Key dates in mifepristone's history • Tennessee Lookout
A timeline provides key dates in the history of mifepristone, from its 1980 development to ongoing Supreme Court arguments.
Source: tennesseelookout.com
Page 8 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Risk Evaluation Today - Breaking & Trending Today
The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says - Merck & Co (NYSE:MRK)
Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients.
Source: benzinga.com
Bristol Myers Squibb to Present Data at on CAMZYOS (mavacamten) for obstructive hypertrophic cardiomyopathy (HCM) at American College of Cardiology Annual Scientific Session, ACC.24
Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.
Source: dicardiology.com
AAD Issues New Guidelines for Clinical Management of Acne Vulgaris
The American Academy of Dermatology issued updated guidelines for the management of acne in adults, adolescents, and preadolescents.
Source: clinicaladvisor.com
